Literature DB >> 29143319

The full spectrum of Castleman disease: 273 patients studied over 20 years.

Eric Oksenhendler1,2,3, David Boutboul1,3, David Fajgenbaum4, Adrien Mirouse1, Claire Fieschi1,3,5,6, Marion Malphettes1,3,5, Laetitia Vercellino7, Véronique Meignin3,8, Laurence Gérard1,2,3, Lionel Galicier1,2,3.   

Abstract

The spectrum of Castleman disease (CD) has considerably extended since its first description in 1956. Recently, an international collaborative working group has reached consensus on the diagnostic criteria and classification of CD. We herein report 273 patients with lymph node histopathology consistent with CD and investigate the newly established diagnostic criteria. Twenty of these patients with Castleman-like histopathology were removed from analyses, because they were diagnosed with an exclusionary disorder (18 with haematological malignancy). Among the 253 remaining patients, 57 were considered unicentric CD (UCD), 169 were multicentric CD associated with Human Herpesvirus 8 (HHV-8+MCD), including 140 patients with human immunodeficiency virus (HIV) infection and 29 patients without HIV infection, and 27 were HHV-8 negative/idiopathic multicentric CD (iMCD). 2-(18 F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography was useful in 62 patients for staging/classification of the disease and for excluding associated lymphoma. UCD was mainly associated with hyaline-vascular histopathological features, and most patients were asymptomatic. Of the 27 patients that we had originally diagnosed with iMCD, 26 met the newly established diagnostic criteria. Patients with iMCD and HHV-8+ MCD demonstrated similar characteristics, including fever, splenomegaly, cytopenia and inflammatory symptoms. However, the disease was more aggressive in HHV-8+ MCD, particularly in HIV-infected patients.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  Castleman disease; HHV-8; HIV; PET-CT

Mesh:

Substances:

Year:  2017        PMID: 29143319     DOI: 10.1111/bjh.15019

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  49 in total

1.  Excellent Outcomes with Surgery or Radiotherapy in the Management of Castleman Disease Including a Case of Oligocentric Disease.

Authors:  Thomas H Beckham; Joanna C Yang; Karen W Chau; Ariela Noy; Joachim Yahalom
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-05-11

Review 2.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Autoimmune hypoglycemia expands the biological spectrum of HHV8+ multicentric Castleman disease.

Authors:  Pierre Arnautou; Martine Auclair; Soraya Fellahi; Clara Bouché; Claire Fieschi; Elias Barrak; Viviane Queyrel-Moranne; Lucy Chaillous; Nicolas Blin; Marion Malphettes; Jehane Fadlallah; Remi Bertinchamp; Laurence Gérard; Djaouida Bengoufa; Lionel Galicier; Eric Oksenhendler; Corinne Vigouroux; David Boutboul
Journal:  Blood Adv       Date:  2021-04-13

4.  A mesorectal incidentaloma: Rare localization of Castleman disease (Case report).

Authors:  Daniel Ion; Alexandra Bolocan; Alexandru George Filipescu; Octavian Andronic; Ana-Maria Oproiu; Adelina Popa; Dan Nicoale Păduraru
Journal:  Exp Ther Med       Date:  2022-02-08       Impact factor: 2.447

Review 5.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

6.  A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study.

Authors:  Li Yu; Menghan Shi; Qingqing Cai; Paolo Strati; Fredrick Hagemeister; Qiongli Zhai; Ling Li; Xiaosheng Fang; Jianyong Li; Ruifang Sun; Shanxiang Zhang; Hanjin Yang; Zhaoming Wang; Wenbin Qian; Noriko Iwaki; Yasuharu Sato; Lu Zhang; Jian Li; Eric Oksenhendler; Zijun Y Xu-Monette; Ken H Young
Journal:  Oncologist       Date:  2020-09-18

7.  Castleman disease in pediatrics: Insights on presentation, treatment, and outcomes from a two-site retrospective cohort study.

Authors:  Jenna Sopfe; Ashley Endres; Kristen Campbell; Kari Hayes; Andrew T Trout; Xiayuan Liang; Robert Lorsbach; Maureen M O'Brien; Carrye R Cost
Journal:  Pediatr Blood Cancer       Date:  2019-01-24       Impact factor: 3.167

8.  Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population.

Authors:  Karen M Chisholm; Mark D Fleming
Journal:  Am J Clin Pathol       Date:  2020-05-05       Impact factor: 2.493

Review 9.  Clinicopathological comparison and therapeutic approach to Castleman disease-a case-based review.

Authors:  Małgorzata Wojtyś; Agnieszka Piekarska; Michał Kunc; Konrad Ptaszyński; Wojciech Biernat; Jan Maciej Zaucha; Piotr Waloszczyk; Piotr Lisowski; Bartosz Kubisa; Tomasz Grodzki
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

Review 10.  KSHV/HHV8-mediated hematologic diseases.

Authors:  Ethel Cesarman; Amy Chadburn; Paul G Rubinstein
Journal:  Blood       Date:  2022-02-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.